Psoriatic Arthritis News

DESTIN, Fla. — The course of difficult-to-treat psoriatic arthritis can be significantly impacted by a host of factors beyond choice of therapy, according to data presented at the Congress of Clinical Rheumatology East annual meeting.

Patients with psoriatic arthritis demonstrated similar disease activity outcomes and drug persistence after long-term treatment with either etanercept or its biosimilar SB4, according to data published in Arthritis Care & Research.

The FDA has approved a citrate-free, high-concentration formulation of the interchangeable adalimumab biosimilar Cyltezo to treat multiple chronic inflammatory diseases, according to the manufacturer.

In this edition, FDA approves Selarsdi as Stelara biosimilar, deucravacitinib improves ‘broad range’ of patient-reported outcomes and more.

Healio spoke with Matthew Lewis, MD, about the risk for psoriatic arthritis in patients with psoriasis.

The FDA has approved Selarsdi as a biosimilar to Stelara for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis, Teva Pharmaceuticals and Alvotech announced in a press release.

Patients with psoriatic arthritis who receive deucravacitinib report significant improvements in mental health, pain, fatigue and other outcomes vs. placebo, according to data published in Arthritis Care & Research.

Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights.

Rheumatologists should turn to biologics as usual treatment in patients with psoriatic arthritis who demonstrate an inadequate response to methotrexate, according to new EULAR recommendations.

Patients with psoriatic arthritis who use guselkumab are more likely to experience meaningful improvements in fatigue and pain if they achieve resolution of enthesitis or dactylitis, according to data published in Clinical Rheumatology.